Get the Stockscreener App
3.65
7.83%
-0.31
After Hours:
3.72
0.07
+1.92%
Eledon Pharmaceuticals Inc stock is traded at $3.65, with a volume of 1.32M.
It is down -7.83% in the last 24 hours and down -6.17% over the past month.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
See More
Previous Close:
$3.96
Open:
$4
24h Volume:
1.32M
Relative Volume:
0.94
Market Cap:
$281.74M
Revenue:
-
Net Income/Loss:
$-78.15M
P/E Ratio:
-4.2576
EPS:
-0.8573
Net Cash Flow:
$-68.89M
1W Performance:
-6.89%
1M Performance:
-6.17%
6M Performance:
+132.48%
1Y Performance:
+33.21%
1-Day Range:
$3.64
$4.092
1-Week Range:
$3.64
$4.4899
52-Week Range:
$1.35
$4.60
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Name
Eledon Pharmaceuticals Inc
Sector
Industry
Phone
949-238-8090
Address
19800 MACARTHUR BLVD., IRVINE
Compare ELDN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
3.65 | 305.66M | 0 | -78.15M | -68.89M | -0.8573 |
VRTX
Vertex Pharmaceuticals Inc
|
479.99 | 120.61B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
620.14 | 65.36B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.65 | 53.02B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
292.51 | 39.26B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
178.17 | 36.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Guggenheim | Buy |
| May-13-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-23-21 | Initiated | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Stock (ELDN) Latest News
Natera’s Prospera test selected for Eledon kidney transplant trial - Investing.com
Natera’s Prospera test selected for Eledon kidney transplant trial By Investing.com - Investing.com Canada
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial - Business Wire
NEWSLETTER: Drug to prevent organ rejection after kidney transplant tops standard treatment in trial - Reuters
Noble Financial Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney TransplantationSlideshow (NASDAQ:ELDN) 2026-06-22 - Seeking Alpha
Eledon Pharmaceuticals Amends Certificate of Incorporation – Key Changes Filed in 8-K SEC Report - Minichart
Leerink raises Eledon Pharmaceuticals price target on trial data - Investing.com
Eledon (NASDAQ: ELDN) holders approve share increase and board slate - Stock Titan
Eledon reports Phase 2 BESTOW kidney transplant data - grafa.com
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Raises Target Price to $8 - Moomoo
Eledon Pharmaceuticals Announces Long-Term Extension Phase 2 BESTOW Results for Tegoprubart in Kidney Transplantation - marketscreener.com
Eledon Pharmaceuticals (ELDN) Presents Promising Phase 2 BESTOW Study Data - GuruFocus
Cantor Fitzgerald reiterates Eledon Pharmaceuticals stock rating on kidney transplant data - Investing.com Nigeria
Eledon Says Mid-Stage Data Shows Tegoprubart Offers Higher Kidney Function, Improved Outcomes Compared with Tacrolimus - marketscreener.com
Eledon reports kidney function benefit for tegoprubart at 18 months - Investing.com
Eledon reports kidney function benefit for tegoprubart at 18 months By Investing.com - Investing.com India
Eledon Presents Long-Term Extension Phase 2 BESTOW Results - GlobeNewswire
Eledon trial shows all 12 diabetes patients achieve insulin independence By Investing.com - Investing.com Nigeria
Eledon Pharma To Present At The American Transplant Congress - RTTNews
Is Eledon Pharmaceuticals (ELDN) outperforming other medical stocks this year? - MSN
Eledon Pharmaceuticals Inc (ELDN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Institutional Confidence - TradingKey
Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year? - Yahoo Finance
ELDN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
symbol__ Stock Quote Price and Forecast - CNN
Noble Financial Sticks to Its Buy Rating for Eledon Pharmaceuticals (ELDN) - The Globe and Mail
Eledon Pharmaceuticals (ELDN) Announces Updated Results From Investigator-Initiated Trial Evaluating tegoprubart - Insider Monkey
10 Hot Biotech Stocks Under $5 to Buy - Insider Monkey
Eledon Pharmaceuticals (ELDN) Reports Promising Results for Tego - GuruFocus
Midday Stock Roundup: Eledon Up 4% on T1D Trial Results - Orange County Business Journal
Eledon Pharmaceuticals stock surges on diabetes trial results By Investing.com - Investing.com South Africa
Eledon Pharmaceuticals stock surges on diabetes trial results - Investing.com
Eledon Pharmaceuticals (ELDN) Reports Promising Results for Tegoprubart in T1D Trials - GuruFocus
Eledon trial shows all 12 diabetes patients achieve insulin independence - Investing.com
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine - The Manila Times
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Eledon Pharmaceuticals Inc (ELDN) Stock Price, Quote, News & History - Benzinga
Eledon presents updated trial data on tegoprubart for type 1 diabetes at ADA 2026. - Pluang
Eledon trial results to be presented at diabetes conference By Investing.com - Investing.com South Africa
Eledon trial results to be presented at diabetes conference - Investing.com
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions - The Manila Times
Type 1 diabetes islet transplant brings updated tegoprubart data to ADA - Stock Titan
Eledon Pharmaceuticals, Inc. - MLQ.ai
Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Breakthrough in Diabetes Treatment with ELDN's New Drug Submissi - GuruFocus
Eledon Pharmaceuticals Inc Stock (ELDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
1.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):